Yes, I think it would matter although it would likely be harder to detect. After all, these patients are all on 'standard of care' as well as being in the BoM trial. A patient not taking the BoM drug (placebo or ABL) is likely to also be noncompliant in the SoC drugs as well. These patients would likely elevate the placebo MACE rate if not weeded out to the extent possible.
Jupe